<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2017.00025</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zwirner</surname> <given-names>Norberto Walter</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/31426"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ziblat</surname> <given-names>Andrea</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/394349"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laboratorio de Fisiopatolog&#x000ED;a de la Inmunidad Innata, Instituto de Biolog&#x000ED;a y Medicina Experimental (IBYME, CONICET)</institution>, <addr-line>Ciudad de Buenos Aires</addr-line>, <country>Argentina</country></aff>
<aff id="aff2"><sup>2</sup><institution>Facultad de Ciencias Exactas y Naturales, Departamento de Qu&#x000ED;mica Biol&#x000F3;gica, Universidad de Buenos Aires</institution>, <addr-line>Ciudad de Buenos Aires</addr-line>, <country>Argentina</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Laurent Brossay, Brown University, USA</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Francisco Borrego, BioCruces Health Research Institute, Spain; Jason Paul Gigley, University of Wyoming, USA</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Norberto Walter Zwirner, <email>norzwi&#x00040;gmail.com</email></corresp>
<fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to NK and Innate Lymphoid Cell Biology, a section of the journal Frontiers in Immunology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>01</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>25</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>01</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2017 Zwirner and Ziblat.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Zwirner and Ziblat</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Natural killer (NK) cells are characterized by their ability to detect and induce apoptosis of susceptible target cells and by secretion of immunoregulatory cytokines such as IFN-&#x003B3;. Activation of these effector functions is triggered upon recognition of tumor and pathogen (mostly virus)-infected cells and because of a bidirectional cross talk that NK cells establish with other cells of myeloid origin such as dendritic cells (DC) and macrophages. A common characteristic of these myeloid cells is their ability to secrete different members of the IL-12 family of cytokines such as IL-12, IL-23, and IL-27 and cytokines such as IL-15 and IL-18. Although the effect of IL-12, IL-15, and IL-18 has been characterized, the effect of IL-23 and IL-27 on NK cells (especially human) remains ill-defined. Particularly, IL-27 is a cytokine with dual functions as it has been described as pro- and as anti-inflammatory in different experimental settings. Recent evidence indicates that this cytokine indeed promotes human NK cell activation, IFN-&#x003B3; secretion, NKp46-dependent NK cell-mediated cytotoxicity, and antibody (Ab)-dependent NK cell-mediated cytotoxicity (ADCC) against monoclonal Ab-coated tumor cells. Remarkably, IL-27 also primes NK cells for IL-18 responsiveness, enhancing these functional responses. Consequently, IL-27 acts as a pro-inflammatory cytokine that, in concert with other DC-derived cytokines, hierarchically contributes to NK cells activation and effector functions, which likely contributes to foster the adaptive immune response in different physiopathological conditions.</p>
</abstract>
<kwd-group>
<kwd>NK cells</kwd>
<kwd>cytokines</kwd>
<kwd>dendritic cells</kwd>
<kwd>cytotoxicity</kwd>
<kwd>immunologic</kwd>
<kwd>innate immunity</kwd>
</kwd-group>
<contract-sponsor id="cn01">Agencia Nacional de Promoci&#x000F3;n Cient&#x000ED;fica y Tecnol&#x000F3;gica<named-content content-type="fundref-id">10.13039/501100003074</named-content></contract-sponsor>
<contract-sponsor id="cn02">Universidad de Buenos Aires<named-content content-type="fundref-id">10.13039/501100005363</named-content></contract-sponsor>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="97"/>
<page-count count="7"/>
<word-count count="6475"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>Natural killer (NK) cells constitute one of the three major lymphoid cell populations in blood. They play a protective role against viral infections and tumors, although additional evidence indicates that NK cells are also key players during immunity against other intracellular pathogens (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). In humans, evidence about their role during viral infections came from the observation that patients with rare primary immunodeficiencies that lead to the absence of NK cells or the presence of dysfunctional NK cells display increased susceptibility to different viruses (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Currently, we know that the relevance of NK cells in immunity goes far beyond viral infections, being active immunoregulatory cells during infections with other pathogens, and also during autoimmune processes and in allograft rejection (<xref ref-type="bibr" rid="B1">1</xref>). Moreover, it has been established that NK cells are abundant in different tissues where they may exert such functions, in particular, immunosurveillance against pathogens (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>From a functional aspect, human and mouse NK cells share the ability to induce apoptosis of susceptible target cells through the secretory and death receptor-mediated pathways (FasL and TRAIL) as well as the capacity to secrete immunoregulatory cytokines (<xref ref-type="bibr" rid="B7">7</xref>). Nevertheless, phenotypic characterization of NK cells in both species is quite different. In mice, NK cells are mostly identified as CD3<sup>&#x02212;</sup> CD49b<sup>&#x0002B;</sup> cells, although in C57BL/6 mice but they can also be characterized as CD3<sup>&#x02212;</sup>CD161b/CD161c<sup>&#x0002B;</sup> cells (better known as CD3<sup>&#x02212;</sup>NK1.1<sup>&#x0002B;</sup> cells) (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B8">8</xref>). In humans, NK cells are characterized as CD3<sup>&#x02212;</sup>CD56<sup>&#x0002B;</sup> cells but can be subdivided into different subpopulations based on a differential expression of CD56 and CD16 (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). The majority of peripheral blood NK cells (about a 90%) are CD3<sup>&#x02212;</sup>CD56<sup>dim</sup>CD16<sup>&#x0002B;</sup>, which display a high content of perforin and granzymes and a strong cytotoxic activity, while the rest of NK cells in blood are CD3<sup>&#x02212;</sup>CD56<sup>bright</sup>CD16<sup>dim/&#x02212;</sup> and produce immunoregulatory cytokines in response to different stimuli (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). This subpopulation of NK cells is highly abundant in second lymph organs, where they instruct dendritic cells (DC) to promote Th1- and cytotoxic CD8 T cell-biased responses, shaping in this way the adaptive immunity (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). Some evidence suggests that CD56<sup>bright</sup>CD16<sup>dim/&#x02212;</sup> can differentiate into CD56<sup>dim</sup>CD16<sup>&#x0002B;</sup> cells upon <italic>in vitro</italic> stimulation, indicating that they may constitute developmental stages of fully mature CD56<sup>dim</sup>CD16<sup>&#x0002B;</sup> NK cells (<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>). NK cell subpopulations also express different chemokine receptors involved in their homing to different anatomical niches (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B18">18</xref>).</p>
<p>Recently, identification of innate immune lymphoid cell populations (ILC), especially in mucosal sites, led to a reclassification of NK cells as members of this extended family of cells of the innate immune response (<xref ref-type="bibr" rid="B19">19</xref>&#x02013;<xref ref-type="bibr" rid="B22">22</xref>). ILC contribute to tissue homeostasis, and they seem to be important players of immunity in mucosal sites. Three groups of ILC populations have been described (ILC1, ILC2, and ILC3), which differ in their transcriptional, phenotypic, and transcriptional signatures, respectively (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Moreover, ILC phenotype and function mirrors the phenotype and function of T cells, indicating that innate immune cells display a similar functional compartmentalization as occurs with adaptive immune cells. NK cells have been classified as a subgroup of ILC1, suggesting that they could be some sort of ancestors or innate counterparts of T helper 1 and cytotoxic T lymphocyte (CTL) cells (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Although all ILC1 express T-bet, respond to IL-12 and IL-15 and share the ability to produce IFN-&#x003B3;, only NK cells express EOMES, which differentiates them from other ILC1 populations (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>A vast array of surface receptors confer NK cells the ability to sense their environment. Direct recognition of target cells through inhibitory and activating receptors is a critical event that determines activation of NK cell-mediated cytotoxicity against susceptible cells (virus-infected or neoplastic cells), preserving healthy cells from such response (<xref ref-type="bibr" rid="B7">7</xref>). Many receptors that recognize discrete ligands expressed on target cells and that trigger NK cell activation or promote inhibition of NK cell-mediated effector functions have been identified and cloned (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B10">10</xref>). The better characterized receptors that regulate target cell recognition and activation by NK cells are CD16 or FcR&#x003B3;III [which mediates antibody (Ab)-recognition of target cells and triggers Ab-dependent cell-mediated cytotoxicity or ADCC], CD314 or NKG2D, the natural cytotoxicity receptors CD335 (NKp46), CD336 (NKp44) and CD337 (NKp30), CD226 (DNAM-1), CD244 (2B4), members of the CD158 or killer immunoglobulin-like receptor (KIR) family that carry a short cytoplasmic tail (KIR2DS and KIR3DS) and CD94/NKG2C, among others (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B23">23</xref>). Conversely, inhibitory receptors that preclude NK cell activation are members of the CD158 or KIR family that carry a long cytoplasmic tail (KIR2DL and KIR3DL), CD94/NKG2A, TIGIT, and CD85j (ILT-2, LILRB1, or LIR-1), among others (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B23">23</xref>).</p>
<p>Natural killer cells not only sense and respond to ligands expressed on the cell surface of target cells. Instead, functional response of NK cells also depends on recognition of soluble factors such as pro-inflammatory cytokines (<xref ref-type="bibr" rid="B24">24</xref>). Nonetheless, other soluble factors also exert immunoregulatory functions on these cells. We and others (<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B30">30</xref>) observed that NK cells express endosomal toll-like receptors (TLRs) and respond to specific agonists. In particular, human NK cells express functional TLR3, TLR7, and TLR9, and stimulation of NK cells with their agonists triggers IFN-&#x003B3; secretion only in the presence of suboptimal concentrations of IL-12 or IFN-&#x003B1; but not IL-15 (<xref ref-type="bibr" rid="B25">25</xref>). This effect was further potentiated by co-engagement of NKG2D, one of the major cell surface receptors involved in recognition and elimination of tumor cells by NK cells, but TLR agonists do not seem to exert immunoregulatory effects on NKG2D-dependent NK cell-mediated cytotoxicity (<xref ref-type="bibr" rid="B5">5</xref>). Therefore, NK cells can sense and integrate signals derived from their surrounding environment, and that are detected by different categories of receptors.</p>
<p>Biological functions of NK cells are tightly regulated during their interaction with DC as a consequence of which NK cells promote maturation of DC and become activated by cell surface receptors such as NKp30 (<xref ref-type="bibr" rid="B31">31</xref>) and DNAM-1 (<xref ref-type="bibr" rid="B32">32</xref>) and cytokines such as IL-12, IL-15, and IL-18 (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B31">31</xref>&#x02013;<xref ref-type="bibr" rid="B35">35</xref>). Remarkably, the consequences of this interaction are not only manifested in NK cells but also impact on the adaptive immunity as NK cells promote maturation of DC and instruct them to shape T cell activation toward Th1- and CTL-mediated responses (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>In this context, an integral analysis of factors that regulate NK cell effector functions may contribute to the development of novel strategies to improve immunosurveillance and promote a sustained tumoricidal capacity of NK cells (<xref ref-type="bibr" rid="B7">7</xref>). Therefore, the focus of our laboratory has been the investigation of how NK cells sense their environment and unravel novel factors that affect their phenotype and functions.</p>
</sec>
<sec id="S2">
<title>Regulation of NK Cell Activation and Effector Functions by IL-27</title>
<p>IL-12 is the first described member of an extended family of cytokines produced mostly by myeloid cells (DC and macrophages) in response to infectious agents and other insults (<xref ref-type="bibr" rid="B36">36</xref>). IL-12 promotes the generation of Th1, IFN-&#x003B3;-producing cells during naive CD4<sup>&#x0002B;</sup> T cell activation (<xref ref-type="bibr" rid="B37">37</xref>). Also, IL-12 produced by macrophages triggers NK cell-mediated IFN-&#x003B3; production during infection with intracellular parasites (<xref ref-type="bibr" rid="B38">38</xref>) and contributes to protection during acute infection (<xref ref-type="bibr" rid="B39">39</xref>). These findings unraveled the existence of a cytokine axis in which myeloid cell-derived IL-12 triggers lymphoid cell-derived IFN-&#x003B3; production and contributes to resistance to infection.</p>
<p>Members of the IL-12 family of heterodimeric cytokines share protein subunits and receptor chains. IL-12 is composed by two subunits, namely, p35 and p40, and is recognized by a heterodimeric receptor composed of two chains IL-12R&#x003B2;1 and IL-12R&#x003B2;2 (<xref ref-type="bibr" rid="B36">36</xref>). Signaling through this receptor activates mainly STAT4, activates T-bet, and leads to IFN-&#x003B3; production in NK and T cells, thus mediating pro-inflammatory effects (<xref ref-type="bibr" rid="B40">40</xref>&#x02013;<xref ref-type="bibr" rid="B42">42</xref>). Since na&#x000EF;ve T cells do not express IL-12R&#x003B2;2, IL-12 alone does not seem to be sufficient to guide T cell activation toward Th1 cells (<xref ref-type="bibr" rid="B43">43</xref>). A similar effect was described for IFN-&#x003B3; production by human and mouse NK cells (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B44">44</xref>&#x02013;<xref ref-type="bibr" rid="B46">46</xref>), suggesting that IL-12 requires a cooperation with other factors to properly exert its effects on NK and T cell-derived IFN-&#x003B3; production. IL-12 also enhances NK cell-mediated cytotoxicity against different target cells, affects expression of some cell surface receptors involved in target cell recognition (<xref ref-type="bibr" rid="B47">47</xref>&#x02013;<xref ref-type="bibr" rid="B49">49</xref>), and, more recently, IL-12 has also been involved in the generation of memory-like NK cells (<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>). IL-12 is secreted by DC and macrophages and has been shown to be a major player of a bidirectional cross talk that they establish with NK or T cells (<xref ref-type="bibr" rid="B36">36</xref>). Also, as a consequence of their cross talk with macrophages, NK cells can stimulate production of nitric oxide (NO) due to upregulation of inducible NO synthase (<xref ref-type="bibr" rid="B52">52</xref>). In addition, as a consequence of their cross talk with DC, NK cells can promote upregulation of costimulatory molecules such as CD86 (<xref ref-type="bibr" rid="B53">53</xref>).</p>
<p>Other members of the IL-12 family of cytokines are IL-23, IL-27, and IL-35 (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B54">54</xref>) which, as mentioned, are heterodimeric proteins that share not only one subunit with another member of the family but also signal through heterodimeric receptors with shared subunits (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). As with IL-12, macrophages and DC can produce IL-23 and IL-27 upon sensing pathogens or their products (<xref ref-type="bibr" rid="B56">56</xref>&#x02013;<xref ref-type="bibr" rid="B59">59</xref>). IL-23 is composed by one subunit shared with IL-12 (p40) that is associated with the p19 subunit to constitute the active form of IL-23. This cytokine signals through a heterodimeric receptor composed of IL-12R&#x003B2;1 and IL-23R, which activates Jak2/Tyk2, STAT1/STAT3/STAT4/STAT5 (<xref ref-type="bibr" rid="B60">60</xref>). IL-23 activates NK cells and in this way, contributes to the antitumor immune response (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Nevertheless, other authors failed to demonstrate an effect of IL-23 on NK cells (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>), making the effects of this cytokine on NK cells an open question that warrants further investigation.</p>
<p>IL-27, in turn, is a heterodimeric cytokine composed by the EBI3 and p28 subunits that signals through a heterodimeric receptor composed by the WSX-1 and CD130/gp130 chains (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B66">66</xref>). As with other members of this familty of cytokines, IL-27 is produced mainly by DC and macrophages upon microbial insults (<xref ref-type="bibr" rid="B55">55</xref>). Paradoxically, IL-27 displays pro- and anti-inflammatory functions due to activation of STAT1 and STAT3, respectively (<xref ref-type="bibr" rid="B36">36</xref>), but its pro-inflammatory effects depend on induction of T-bet and IL-12R&#x003B2;2 expression (<xref ref-type="bibr" rid="B67">67</xref>&#x02013;<xref ref-type="bibr" rid="B69">69</xref>). In line with a dual role of IL-27, it has been shown that this cytokine prevents tissue damage induced by excessive inflammation (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B70">70</xref>). The effect of IL-27 on NK cells and their ability to control tumor growth have been described in some mouse models (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B70">70</xref>&#x02013;<xref ref-type="bibr" rid="B76">76</xref>), while in other tumor models, an effect of IL-27 on NK cells was not observed (<xref ref-type="bibr" rid="B77">77</xref>). Therefore, the effects of IL-27 on mouse NK cells might be tumor-type dependent. In humans, it was reported that IL-27 can costimulate NK cells for IFN-&#x003B3; gene expression (<xref ref-type="bibr" rid="B78">78</xref>), while we observed that mature DC secrete IL-27 and that this cytokine contributes to NK cell activation and effector functions (<xref ref-type="bibr" rid="B79">79</xref>). Indeed, IL-27 can directly trigger IFN-&#x003B3; secretion through activation of STAT1 and promote activation of NK cells (upregulation of CD25 and CD69). IL-27 also promotes upregulation of NKp46 and subsequent NKp46-dependent NK cell-mediated cytotoxicity against target cells that are otherwise resistant to NK cell-mediated cytotoxicity, through the secretory pathway and TRAIL (<xref ref-type="bibr" rid="B79">79</xref>). IL-27 also potentiates ADCC induced by therapeutic monoclonal antibodies such as rituximab, trastuzumab, and cetuximab, suggesting that IL-27 may be helpful as adjuvant during immunotherapy in human patients (<xref ref-type="bibr" rid="B79">79</xref>). The effects of IL-27 on NK cells are summarized in Figure <xref ref-type="fig" rid="F1">1</xref>.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p><bold>Summary of cytokine axis involving IL-27 in human natural killer (NK) cell activation</bold>. Mature DC (mDC) secrete IL-12, IL-27, and IL-18, among others. During the cross talk between mDC and NK cells (and besides the known effect of IL-12), IL-27, alone or in concert with IL-18, triggers NK cell activation (upregulation of CD25 and CD69), IFN-&#x003B3; production, and cytotoxicity against target cells that are otherwise resistant to non-stimulated NK cells. Such cytotoxic response involves recognition of target cells through NKp46- and CD16-dependent mechanisms (ADCC) and induction of target cell apoptosis <italic>via</italic> granule exocytosis and TRAIL-mediated mechanisms. Moreover, IL-27 also primes NK cells for IL-18-mediated augmented IFN-&#x003B3; secretion which in turn upregulates ICAM-1 on target cells, facilitates the formation of NK cell&#x02013;target cell conjugates, and therefore further increases the cytotoxic activity of NK cells. Since IL-18 primes NK cells for IL-12 responsiveness, IL-27-driven priming of NK cells for IL-18 may also contribute to further potentiate IL-12 responsiveness and fostering NK cell effector functions.</p></caption>
<graphic xlink:href="fimmu-08-00025-g001.tif"/>
</fig>
</sec>
<sec id="S3">
<title>Cooperation Between Cytokines for NK Cell Stimulation: The Case of IL-27 and IL-18</title>
<p>Cooperative effect of cytokines, in particular those secreted by DC and macrophages, has been described for many of them and reviewed elsewhere (<xref ref-type="bibr" rid="B24">24</xref>). Briefly, cooperative effects of IL-12 and IL-2 or IL-15 (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>), IL-2 and IL-15 (<xref ref-type="bibr" rid="B82">82</xref>), IL-12 and IL-18 (<xref ref-type="bibr" rid="B81">81</xref>, <xref ref-type="bibr" rid="B83">83</xref>&#x02013;<xref ref-type="bibr" rid="B85">85</xref>) for NK cell activation, IFN-&#x003B3; production, and cytotoxicity have been described. In most cases, underlying mechanisms of cytokine cooperation for NK cell activation remain ill-defined. IL-18 belongs to the IL-1 superfamily and has the peculiarity of having a critical effect on NK cells (<xref ref-type="bibr" rid="B86">86</xref>). IL-18 seems to play a major role as &#x0201C;cooperating cytokine&#x0201D; for NK cell activation and elicitation of effector functions (<xref ref-type="bibr" rid="B87">87</xref>, <xref ref-type="bibr" rid="B88">88</xref>). Accordingly, NK cells from IL-18<sup>&#x02212;/&#x02212;</sup> mice display a deep impaired immune response against tumors and cannot be properly stimulated <italic>in vivo</italic> with IL-12 to secrete IFN-&#x003B3; (<xref ref-type="bibr" rid="B89">89</xref>). These and other experimental results led to the notion that IL-18 actually primes NK cells to become responsive to IL-12 (<xref ref-type="bibr" rid="B89">89</xref>&#x02013;<xref ref-type="bibr" rid="B91">91</xref>). Remarkably, we demonstrated that IL-27 also primes NK cells but for IL-18-mediated IFN-&#x003B3; secretion inducing upregulation of T-bet expression in NK cells (<xref ref-type="bibr" rid="B79">79</xref>). T-bet is a critical transcription factor that regulates IFN-&#x003B3; production (<xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>) by promoting IFN-&#x003B3; gene transcription (<xref ref-type="bibr" rid="B94">94</xref>). Moreover, cooperation between IL-27 and IL-18 enhances NK cell-mediated cytotoxicity through the secretory pathway and TRAIL and involves NK cell-derived IFN-&#x003B3;. This is because IFN-&#x003B3; secretion during effector&#x02013;target cell contact increases the percentage of ICAM-1<sup>&#x0002B;</sup> target cells that in turn facilitates the formation of NK cell&#x02013;target cell conjugates and delivery of the cytotoxic hit (<xref ref-type="bibr" rid="B95">95</xref>). These effects are summarized in Figure <xref ref-type="fig" rid="F1">1</xref>.</p>
<p>As DC and macrophages stimulated with microbial products or tumor cells can secrete IL-12, IL-18, and IL-27 (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B73">73</xref>), it is possible that stimulatory effects of IL-27 may occur when DC or macrophages secrete this cytokine and establish a bidirectional cross talk with NK cells. During this cross talk, IL-27 may prime NK cells for IL-18 responsiveness, while IL-18 secreted at the synaptic cleft between NK cells and DC (<xref ref-type="bibr" rid="B91">91</xref>) may in turn prime NK cells for IL-12 responsiveness (<xref ref-type="bibr" rid="B90">90</xref>). Although a kinetic analysis of the production of these cytokines needs to be performed to establish the temporal relationship in their secretion, the cooperation between IL-27 and IL-18 that we described unravels the existence of a hierarchical cytokine network that is relevant during DC-NK cell cross talk that generates fully functional NK cells. In line with this hierarchical cytokine network in NK cell activation is the fact that IL-27 can initiate Th1 development by na&#x000EF;ve T cells by promoting activation of STAT1 and STAT3, expression of T-bet, repression of GATA3 (involved in Th2 differentiation), and production of IL-12R&#x003B2;2 chain (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>). These changes in CD4 T cells during activation confer them the ability to sense DC-derived IL-12 and consequently follow the path of Th1 differentiation, leading to secretion of IFN-&#x003B3;.</p>
<p>Collectively, the cytokine axis composed of IL-27/IL-18/IL-12 is indeed involved in optimal NK cell activation and in skewing CD4 T cell responses through a cross talk between these lymphoid cells (NK cells and T cells) and myeloid cells (DC), representing an important link between innate and adaptive immunity.</p>
</sec>
<sec id="S4">
<title>Concluding Remarks</title>
<p>Natural killer cells are currently viewed not only as cytotoxic cells but also as strong producers of immunoregulatory cytokines, in particular, IFN-&#x003B3;. They belong to the family of ILC, and their effector functions are tightly regulated by interaction with DC and other cells of myeloid lineage, which secrete cytokines with NK cell-stimulating activity. IL-12 is one of the most relevant cytokines produced by myeloid cells that promote NK cell activation. The discovery of other members of the IL-12 family of cytokines, such as IL-23 and IL-27, and exploration of cooperation between cytokines for NK cell activation have established that NK cells also become activated by IL-27. Interestingly, IL-27 not only exerts direct effects on NK cells but also primes them for IL-18-responsiveness, which unveils another aspect of the intricate cytokine network that regulates NK cell biological functions and that further demonstrates a hierarchical effect of different cytokines on these cells. Consequently, NK cells display the ability to integrate multiple signals from their environment and adjust their effector functions accordingly, probably to optimize the magnitude of their response to pathogens and tumor cells and shape adaptive immunity in different physiopathological conditions.</p>
</sec>
<sec id="S5" sec-type="author-contributor">
<title>Author Contributions</title>
<p>NZ designed and wrote the review and prepared the figures. AZ revised the manuscript and figures.</p>
</sec>
<sec id="S6">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank to past and current lab members. This work was supported by grants from the National Agency for Promotion of Science and Technology from Argentina (ANPCYT), the National Research Council of Argentina (CONICET), and the University of Buenos Aires (UBA), all to NZ. The authors also thank to Fundaci&#x000F3;n Williams and Fundaci&#x000F3;n Ren&#x000E9; Bar&#x000F3;n for providing financial assistance (donations) to their laboratory. NZ is a member of the Researcher Career of CONICET and professor at UBA. AZ is a postdoctoral fellow of CONICET.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>KC</given-names></name> <name><surname>Riley</surname> <given-names>EM</given-names></name></person-group>. <article-title>Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens</article-title>. <source>Nat Rev Immunol</source> (<year>2007</year>) <volume>7</volume>(<issue>4</issue>):<fpage>279</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/nri2057</pub-id><pub-id pub-id-type="pmid">17380157</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname> <given-names>LL</given-names></name></person-group>. <article-title>Up on the tightrope: natural killer cell activation and inhibition</article-title>. <source>Nat Immunol</source> (<year>2008</year>) <volume>9</volume>(<issue>5</issue>):<fpage>495</fpage>&#x02013;<lpage>502</lpage>.<pub-id pub-id-type="doi">10.1038/ni1581</pub-id><pub-id pub-id-type="pmid">18425106</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orange</surname> <given-names>JS</given-names></name> <name><surname>Brodeur</surname> <given-names>SR</given-names></name> <name><surname>Jain</surname> <given-names>A</given-names></name> <name><surname>Bonilla</surname> <given-names>FA</given-names></name> <name><surname>Schneider</surname> <given-names>LC</given-names></name> <name><surname>Kretschmer</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations</article-title>. <source>J Clin Invest</source> (<year>2002</year>) <volume>109</volume>(<issue>11</issue>):<fpage>1501</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1172/JCI14858</pub-id><pub-id pub-id-type="pmid">12045264</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orange</surname> <given-names>JS</given-names></name></person-group>. <article-title>Unraveling human natural killer cell deficiency</article-title>. <source>J Clin Invest</source> (<year>2012</year>) <volume>122</volume>(<issue>3</issue>):<fpage>798</fpage>&#x02013;<lpage>801</lpage>.<pub-id pub-id-type="doi">10.1172/JCI62620</pub-id><pub-id pub-id-type="pmid">22354165</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carrega</surname> <given-names>P</given-names></name> <name><surname>Ferlazzo</surname> <given-names>G</given-names></name></person-group>. <article-title>Natural killer cell distribution and trafficking in human tissues</article-title>. <source>Front Immunol</source> (<year>2012</year>) <volume>3</volume>:<fpage>347</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2012.00347</pub-id><pub-id pub-id-type="pmid">23230434</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melsen</surname> <given-names>JE</given-names></name> <name><surname>Lugthart</surname> <given-names>G</given-names></name> <name><surname>Lankester</surname> <given-names>AC</given-names></name> <name><surname>Schilham</surname> <given-names>MV</given-names></name></person-group>. <article-title>Human circulating and tissue-resident CD56(bright) natural killer cell populations</article-title>. <source>Front Immunol</source> (<year>2016</year>) <volume>7</volume>:<fpage>262</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2016.00262</pub-id><pub-id pub-id-type="pmid">27446091</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morvan</surname> <given-names>MG</given-names></name> <name><surname>Lanier</surname> <given-names>LL</given-names></name></person-group>. <article-title>NK cells and cancer: you can teach innate cells new tricks</article-title>. <source>Nat Rev Cancer</source> (<year>2016</year>) <volume>16</volume>(<issue>1</issue>):<fpage>7</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1038/nrc.2015.5</pub-id><pub-id pub-id-type="pmid">26694935</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geiger</surname> <given-names>TL</given-names></name> <name><surname>Sun</surname> <given-names>JC</given-names></name></person-group>. <article-title>Development and maturation of natural killer cells</article-title>. <source>Curr Opin Immunol</source> (<year>2016</year>) <volume>39</volume>:<fpage>82</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2016.01.007</pub-id><pub-id pub-id-type="pmid">26845614</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moretta</surname> <given-names>A</given-names></name></person-group>. <article-title>Natural killer cells and dendritic cells: rendezvous in abused tissues</article-title>. <source>Nat Rev Immunol</source> (<year>2002</year>) <volume>2</volume>(<issue>12</issue>):<fpage>957</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1038/nri956</pub-id><pub-id pub-id-type="pmid">12461568</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moretta</surname> <given-names>A</given-names></name> <name><surname>Marcenaro</surname> <given-names>E</given-names></name> <name><surname>Parolini</surname> <given-names>S</given-names></name> <name><surname>Ferlazzo</surname> <given-names>G</given-names></name> <name><surname>Moretta</surname> <given-names>L</given-names></name></person-group>. <article-title>NK cells at the interface between innate and adaptive immunity</article-title>. <source>Cell Death Differ</source> (<year>2008</year>) <volume>15</volume>(<issue>2</issue>):<fpage>226</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1038/sj.cdd.4402170</pub-id><pub-id pub-id-type="pmid">17541426</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caligiuri</surname> <given-names>MA</given-names></name></person-group>. <article-title>Human natural killer cells</article-title>. <source>Blood</source> (<year>2008</year>) <volume>112</volume>(<issue>3</issue>):<fpage>461</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2007-09-077438</pub-id><pub-id pub-id-type="pmid">18650461</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strowig</surname> <given-names>T</given-names></name> <name><surname>Brilot</surname> <given-names>F</given-names></name> <name><surname>Munz</surname> <given-names>C</given-names></name></person-group>. <article-title>Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>(<issue>12</issue>):<fpage>7785</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.180.12.7785</pub-id><pub-id pub-id-type="pmid">18523242</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferlazzo</surname> <given-names>G</given-names></name> <name><surname>Pack</surname> <given-names>M</given-names></name> <name><surname>Thomas</surname> <given-names>D</given-names></name> <name><surname>Paludan</surname> <given-names>C</given-names></name> <name><surname>Schmid</surname> <given-names>D</given-names></name> <name><surname>Strowig</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2004</year>) <volume>101</volume>(<issue>47</issue>):<fpage>16606</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0407522101</pub-id><pub-id pub-id-type="pmid">15536127</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferlazzo</surname> <given-names>G</given-names></name> <name><surname>Thomas</surname> <given-names>D</given-names></name> <name><surname>Lin</surname> <given-names>SL</given-names></name> <name><surname>Goodman</surname> <given-names>K</given-names></name> <name><surname>Morandi</surname> <given-names>B</given-names></name> <name><surname>Muller</surname> <given-names>WA</given-names></name> <etal/></person-group> <article-title>The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>172</volume>(<issue>3</issue>):<fpage>1455</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.172.3.1455</pub-id><pub-id pub-id-type="pmid">14734722</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>A</given-names></name> <name><surname>Hong</surname> <given-names>DL</given-names></name> <name><surname>Atzberger</surname> <given-names>A</given-names></name> <name><surname>Kollnberger</surname> <given-names>S</given-names></name> <name><surname>Filer</surname> <given-names>AD</given-names></name> <name><surname>Buckley</surname> <given-names>CD</given-names></name> <etal/></person-group> <article-title>CD56<sup>bright</sup> human NK cells differentiate into CD56<sup>dim</sup> cells: role of contact with peripheral fibroblasts</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>179</volume>(<issue>1</issue>):<fpage>89</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.179.1.89</pub-id><pub-id pub-id-type="pmid">17579025</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romagnani</surname> <given-names>C</given-names></name> <name><surname>Juelke</surname> <given-names>K</given-names></name> <name><surname>Falco</surname> <given-names>M</given-names></name> <name><surname>Morandi</surname> <given-names>B</given-names></name> <name><surname>D&#x02019;Agostino</surname> <given-names>A</given-names></name> <name><surname>Costa</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>CD56<sup>bright</sup>CD16<sup>-</sup> killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56<sup>dim</sup> NK cells upon activation</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>8</issue>):<fpage>4947</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.8.4947</pub-id><pub-id pub-id-type="pmid">17404276</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luetke-Eversloh</surname> <given-names>M</given-names></name> <name><surname>Killig</surname> <given-names>M</given-names></name> <name><surname>Romagnani</surname> <given-names>C</given-names></name></person-group>. <article-title>Signatures of human NK cell development and terminal differentiation</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4</volume>:<fpage>499</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2013.00499</pub-id><pub-id pub-id-type="pmid">24416035</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>JJ</given-names></name> <name><surname>Qin</surname> <given-names>S</given-names></name> <name><surname>Unutmaz</surname> <given-names>D</given-names></name> <name><surname>Soler</surname> <given-names>D</given-names></name> <name><surname>Murphy</surname> <given-names>KE</given-names></name> <name><surname>Hodge</surname> <given-names>MR</given-names></name> <etal/></person-group> <article-title>Unique subpopulations of CD56<sup>&#x0002B;</sup> NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>(<issue>11</issue>):<fpage>6477</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.166.11.6477</pub-id><pub-id pub-id-type="pmid">11359797</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname> <given-names>M</given-names></name> <name><surname>Miller</surname> <given-names>H</given-names></name> <name><surname>Song</surname> <given-names>C</given-names></name></person-group>. <article-title>Beyond NK cells: the expanding universe of innate lymphoid cells</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<fpage>282</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2014.00282</pub-id><pub-id pub-id-type="pmid">24982658</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spits</surname> <given-names>H</given-names></name> <name><surname>Artis</surname> <given-names>D</given-names></name> <name><surname>Colonna</surname> <given-names>M</given-names></name> <name><surname>Diefenbach</surname> <given-names>A</given-names></name> <name><surname>Di Santo</surname> <given-names>JP</given-names></name> <name><surname>Eberl</surname> <given-names>G</given-names></name> <etal/></person-group> <article-title>Innate lymphoid cells &#x02013; a proposal for uniform nomenclature</article-title>. <source>Nat Rev Immunol</source> (<year>2013</year>) <volume>13</volume>(<issue>2</issue>):<fpage>145</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nri3365</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname> <given-names>AN</given-names></name> <name><surname>Spits</surname> <given-names>H</given-names></name> <name><surname>Eberl</surname> <given-names>G</given-names></name></person-group>. <article-title>Innate lymphoid cells in inflammation and immunity</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>(<issue>3</issue>):<fpage>366</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.09.006</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diefenbach</surname> <given-names>A</given-names></name> <name><surname>Colonna</surname> <given-names>M</given-names></name> <name><surname>Koyasu</surname> <given-names>S</given-names></name></person-group>. <article-title>Development, differentiation, and diversity of innate lymphoid cells</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>(<issue>3</issue>):<fpage>354</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.09.005</pub-id><pub-id pub-id-type="pmid">25238093</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname> <given-names>Y</given-names></name> <name><surname>Bauer</surname> <given-names>B</given-names></name> <name><surname>Steinle</surname> <given-names>A</given-names></name></person-group>. <article-title>Modulation of NK cell function by genetically coupled C-type lectin-like receptor/ligand pairs encoded in the human natural killer gene complex</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4</volume>:<fpage>362</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2013.00362</pub-id><pub-id pub-id-type="pmid">24223577</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zwirner</surname> <given-names>NW</given-names></name> <name><surname>Domaica</surname> <given-names>CI</given-names></name></person-group>. <article-title>Cytokine regulation of natural killer cell effector functions</article-title>. <source>Biofactors</source> (<year>2010</year>) <volume>36</volume>(<issue>4</issue>):<fpage>274</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1002/biof.107</pub-id><pub-id pub-id-type="pmid">20623510</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girart</surname> <given-names>MV</given-names></name> <name><surname>Fuertes</surname> <given-names>MB</given-names></name> <name><surname>Domaica</surname> <given-names>CI</given-names></name> <name><surname>Rossi</surname> <given-names>LE</given-names></name> <name><surname>Zwirner</surname> <given-names>NW</given-names></name></person-group>. <article-title>Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>179</volume>(<issue>6</issue>):<fpage>3472</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.179.6.3472</pub-id><pub-id pub-id-type="pmid">17804388</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chalifour</surname> <given-names>A</given-names></name> <name><surname>Jeannin</surname> <given-names>P</given-names></name> <name><surname>Gauchat</surname> <given-names>JF</given-names></name> <name><surname>Blaecke</surname> <given-names>A</given-names></name> <name><surname>Malissard</surname> <given-names>M</given-names></name> <name><surname>N&#x02019;Guyen</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production</article-title>. <source>Blood</source> (<year>2004</year>) <volume>104</volume>(<issue>6</issue>):<fpage>1778</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2003-08-2820</pub-id><pub-id pub-id-type="pmid">15166032</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname> <given-names>OM</given-names></name> <name><surname>Athie-Morales</surname> <given-names>V</given-names></name> <name><surname>O&#x02019;Connor</surname> <given-names>GM</given-names></name> <name><surname>Gardiner</surname> <given-names>CM</given-names></name></person-group>. <article-title>TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production</article-title>. <source>J Immunol</source> (<year>2005</year>) <volume>175</volume>(<issue>3</issue>):<fpage>1636</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.175.3.1636</pub-id><pub-id pub-id-type="pmid">16034103</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sivori</surname> <given-names>S</given-names></name> <name><surname>Falco</surname> <given-names>M</given-names></name> <name><surname>Della Chiesa</surname> <given-names>M</given-names></name> <name><surname>Carlomagno</surname> <given-names>S</given-names></name> <name><surname>Vitale</surname> <given-names>M</given-names></name> <name><surname>Moretta</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>CpG and double-stranded RNA trigger human NK cells by toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2004</year>) <volume>101</volume>(<issue>27</issue>):<fpage>10116</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0403744101</pub-id><pub-id pub-id-type="pmid">15218108</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorski</surname> <given-names>KS</given-names></name> <name><surname>Waller</surname> <given-names>EL</given-names></name> <name><surname>Bjornton-Severson</surname> <given-names>J</given-names></name> <name><surname>Hanten</surname> <given-names>JA</given-names></name> <name><surname>Riter</surname> <given-names>CL</given-names></name> <name><surname>Kieper</surname> <given-names>WC</given-names></name> <etal/></person-group> <article-title>Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists</article-title>. <source>Int Immunol</source> (<year>2006</year>) <volume>18</volume>(<issue>7</issue>):<fpage>1115</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1093/intimm/dxl046</pub-id><pub-id pub-id-type="pmid">16728430</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname> <given-names>KN</given-names></name> <name><surname>Leung</surname> <given-names>B</given-names></name> <name><surname>Kwong</surname> <given-names>M</given-names></name> <name><surname>Zarember</surname> <given-names>KA</given-names></name> <name><surname>Satyal</surname> <given-names>S</given-names></name> <name><surname>Navas</surname> <given-names>TA</given-names></name> <etal/></person-group> <article-title>APC-independent activation of NK cells by the toll-like receptor 3 agonist double-stranded RNA</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>172</volume>(<issue>1</issue>):<fpage>138</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.172.1.138</pub-id><pub-id pub-id-type="pmid">14688319</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferlazzo</surname> <given-names>G</given-names></name> <name><surname>Tsang</surname> <given-names>ML</given-names></name> <name><surname>Moretta</surname> <given-names>L</given-names></name> <name><surname>Melioli</surname> <given-names>G</given-names></name> <name><surname>Steinman</surname> <given-names>RM</given-names></name> <name><surname>Munz</surname> <given-names>C</given-names></name></person-group>. <article-title>Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells</article-title>. <source>J Exp Med</source> (<year>2002</year>) <volume>195</volume>(<issue>3</issue>):<fpage>343</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20011149</pub-id><pub-id pub-id-type="pmid">11828009</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pende</surname> <given-names>D</given-names></name> <name><surname>Castriconi</surname> <given-names>R</given-names></name> <name><surname>Romagnani</surname> <given-names>P</given-names></name> <name><surname>Spaggiari</surname> <given-names>GM</given-names></name> <name><surname>Marcenaro</surname> <given-names>S</given-names></name> <name><surname>Dondero</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction</article-title>. <source>Blood</source> (<year>2006</year>) <volume>107</volume>(<issue>5</issue>):<fpage>2030</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2005-07-2696</pub-id><pub-id pub-id-type="pmid">16304049</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin-Fontecha</surname> <given-names>A</given-names></name> <name><surname>Thomsen</surname> <given-names>LL</given-names></name> <name><surname>Brett</surname> <given-names>S</given-names></name> <name><surname>Gerard</surname> <given-names>C</given-names></name> <name><surname>Lipp</surname> <given-names>M</given-names></name> <name><surname>Lanzavecchia</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming</article-title>. <source>Nat Immunol</source> (<year>2004</year>) <volume>5</volume>(<issue>12</issue>):<fpage>1260</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1038/ni1138</pub-id><pub-id pub-id-type="pmid">15531883</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spaggiari</surname> <given-names>GM</given-names></name> <name><surname>Carosio</surname> <given-names>R</given-names></name> <name><surname>Pende</surname> <given-names>D</given-names></name> <name><surname>Marcenaro</surname> <given-names>S</given-names></name> <name><surname>Rivera</surname> <given-names>P</given-names></name> <name><surname>Zocchi</surname> <given-names>MR</given-names></name> <etal/></person-group> <article-title>NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46</article-title>. <source>Eur J Immunol</source> (<year>2001</year>) <volume>31</volume>(<issue>6</issue>):<fpage>1656</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1002/1521-4141(200106)31:6&#x0003C;1656:AID-IMMU1656&#x0003E;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">11385609</pub-id></citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walzer</surname> <given-names>T</given-names></name> <name><surname>Dalod</surname> <given-names>M</given-names></name> <name><surname>Robbins</surname> <given-names>SH</given-names></name> <name><surname>Zitvogel</surname> <given-names>L</given-names></name> <name><surname>Vivier</surname> <given-names>E</given-names></name></person-group>. <article-title>Natural-killer cells and dendritic cells: &#x0201C;l&#x02019;union fait la force&#x0201D;</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>7</issue>):<fpage>2252</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2005-03-1154</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vignali</surname> <given-names>DA</given-names></name> <name><surname>Kuchroo</surname> <given-names>VK</given-names></name></person-group>. <article-title>IL-12 family cytokines: immunological playmakers</article-title>. <source>Nat Immunol</source> (<year>2012</year>) <volume>13</volume>(<issue>8</issue>):<fpage>722</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2366</pub-id><pub-id pub-id-type="pmid">22814351</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seder</surname> <given-names>RA</given-names></name> <name><surname>Gazzinelli</surname> <given-names>R</given-names></name> <name><surname>Sher</surname> <given-names>A</given-names></name> <name><surname>Paul</surname> <given-names>WE</given-names></name></person-group>. <article-title>Interleukin 12 acts directly on CD4<sup>&#x0002B;</sup> T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1993</year>) <volume>90</volume>(<issue>21</issue>):<fpage>10188</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.90.21.10188</pub-id><pub-id pub-id-type="pmid">7901851</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gazzinelli</surname> <given-names>RT</given-names></name> <name><surname>Hieny</surname> <given-names>S</given-names></name> <name><surname>Wynn</surname> <given-names>TA</given-names></name> <name><surname>Wolf</surname> <given-names>S</given-names></name> <name><surname>Sher</surname> <given-names>A</given-names></name></person-group>. <article-title>Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1993</year>) <volume>90</volume>(<issue>13</issue>):<fpage>6115</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.90.13.6115</pub-id><pub-id pub-id-type="pmid">8100999</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gazzinelli</surname> <given-names>RT</given-names></name> <name><surname>Wysocka</surname> <given-names>M</given-names></name> <name><surname>Hayashi</surname> <given-names>S</given-names></name> <name><surname>Denkers</surname> <given-names>EY</given-names></name> <name><surname>Hieny</surname> <given-names>S</given-names></name> <name><surname>Caspar</surname> <given-names>P</given-names></name> <etal/></person-group> <article-title>Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with <italic>Toxoplasma gondii</italic></article-title>. <source>J Immunol</source> (<year>1994</year>) <volume>153</volume>(<issue>6</issue>):<fpage>2533</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">7915739</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname> <given-names>NG</given-names></name> <name><surname>Szabo</surname> <given-names>SJ</given-names></name> <name><surname>Weber-Nordt</surname> <given-names>RM</given-names></name> <name><surname>Zhong</surname> <given-names>Z</given-names></name> <name><surname>Schreiber</surname> <given-names>RD</given-names></name> <name><surname>Darnell</surname> <given-names>JE</given-names> <suffix>Jr</suffix></name> <etal/></person-group> <article-title>Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4</article-title>. <source>J Exp Med</source> (<year>1995</year>) <volume>181</volume>(<issue>5</issue>):<fpage>1755</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1084/jem.181.5.1755</pub-id><pub-id pub-id-type="pmid">7722452</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thierfelder</surname> <given-names>WE</given-names></name> <name><surname>van Deursen</surname> <given-names>JM</given-names></name> <name><surname>Yamamoto</surname> <given-names>K</given-names></name> <name><surname>Tripp</surname> <given-names>RA</given-names></name> <name><surname>Sarawar</surname> <given-names>SR</given-names></name> <name><surname>Carson</surname> <given-names>RT</given-names></name> <etal/></person-group> <article-title>Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells</article-title>. <source>Nature</source> (<year>1996</year>) <volume>382</volume>(<issue>6587</issue>):<fpage>171</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/382171a0</pub-id><pub-id pub-id-type="pmid">8700208</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname> <given-names>MH</given-names></name> <name><surname>Sun</surname> <given-names>YL</given-names></name> <name><surname>Hoey</surname> <given-names>T</given-names></name> <name><surname>Grusby</surname> <given-names>MJ</given-names></name></person-group>. <article-title>Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice</article-title>. <source>Nature</source> (<year>1996</year>) <volume>382</volume>(<issue>6587</issue>):<fpage>174</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/382174a0</pub-id><pub-id pub-id-type="pmid">8700209</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname> <given-names>SJ</given-names></name> <name><surname>Dighe</surname> <given-names>AS</given-names></name> <name><surname>Gubler</surname> <given-names>U</given-names></name> <name><surname>Murphy</surname> <given-names>KM</given-names></name></person-group>. <article-title>Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells</article-title>. <source>J Exp Med</source> (<year>1997</year>) <volume>185</volume>(<issue>5</issue>):<fpage>817</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1084/jem.185.5.817</pub-id><pub-id pub-id-type="pmid">9120387</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>KB</given-names></name> <name><surname>Salazar-Mather</surname> <given-names>TP</given-names></name> <name><surname>Dalod</surname> <given-names>MY</given-names></name> <name><surname>Van Deusen</surname> <given-names>JB</given-names></name> <name><surname>Wei</surname> <given-names>XQ</given-names></name> <name><surname>Liew</surname> <given-names>FY</given-names></name> <etal/></person-group> <article-title>Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>169</volume>(<issue>8</issue>):<fpage>4279</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.169.8.4279</pub-id><pub-id pub-id-type="pmid">12370359</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andoniou</surname> <given-names>CE</given-names></name> <name><surname>van Dommelen</surname> <given-names>SL</given-names></name> <name><surname>Voigt</surname> <given-names>V</given-names></name> <name><surname>Andrews</surname> <given-names>DM</given-names></name> <name><surname>Brizard</surname> <given-names>G</given-names></name> <name><surname>Asselin-Paturel</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity</article-title>. <source>Nat Immunol</source> (<year>2005</year>) <volume>6</volume>(<issue>10</issue>):<fpage>1011</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/ni1244</pub-id><pub-id pub-id-type="pmid">16142239</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loza</surname> <given-names>MJ</given-names></name> <name><surname>Perussia</surname> <given-names>B</given-names></name></person-group>. <article-title>The IL-12 signature: NK cell terminal CD56<sup>&#x0002B;high</sup> stage and effector functions</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>172</volume>(<issue>1</issue>):<fpage>88</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.172.1.88</pub-id><pub-id pub-id-type="pmid">14688313</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname> <given-names>W</given-names></name> <name><surname>Osaki</surname> <given-names>T</given-names></name> <name><surname>Okamura</surname> <given-names>H</given-names></name> <name><surname>Robbins</surname> <given-names>PD</given-names></name> <name><surname>Kurimoto</surname> <given-names>M</given-names></name> <name><surname>Nagata</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>163</volume>(<issue>2</issue>):<fpage>583</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10395644</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname> <given-names>T</given-names></name> <name><surname>Takeda</surname> <given-names>K</given-names></name> <name><surname>Shimozato</surname> <given-names>O</given-names></name> <name><surname>Hayakawa</surname> <given-names>Y</given-names></name> <name><surname>Atsuta</surname> <given-names>M</given-names></name> <name><surname>Kobayashi</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12</article-title>. <source>Eur J Immunol</source> (<year>1999</year>) <volume>29</volume>(<issue>4</issue>):<fpage>1390</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199904)29:04&#x0003C;1390:AID-IMMU1390&#x0003E;3.0.CO;2-C</pub-id><pub-id pub-id-type="pmid">10229107</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orange</surname> <given-names>JS</given-names></name> <name><surname>Wang</surname> <given-names>B</given-names></name> <name><surname>Terhorst</surname> <given-names>C</given-names></name> <name><surname>Biron</surname> <given-names>CA</given-names></name></person-group>. <article-title>Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration</article-title>. <source>J Exp Med</source> (<year>1995</year>) <volume>182</volume>(<issue>4</issue>):<fpage>1045</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1084/jem.182.4.1045</pub-id><pub-id pub-id-type="pmid">7561678</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname> <given-names>MA</given-names></name> <name><surname>Elliott</surname> <given-names>JM</given-names></name> <name><surname>Keyel</surname> <given-names>PA</given-names></name> <name><surname>Yang</surname> <given-names>L</given-names></name> <name><surname>Carrero</surname> <given-names>JA</given-names></name> <name><surname>Yokoyama</surname> <given-names>WM</given-names></name></person-group>. <article-title>Cytokine-induced memory-like natural killer cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2009</year>) <volume>106</volume>(<issue>6</issue>):<fpage>1915</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0813192106</pub-id><pub-id pub-id-type="pmid">19181844</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname> <given-names>TE</given-names></name> <name><surname>Sun</surname> <given-names>JC</given-names></name> <name><surname>Lanier</surname> <given-names>LL</given-names></name></person-group>. <article-title>Natural killer cell memory</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>43</volume>(<issue>4</issue>):<fpage>634</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.09.013</pub-id><pub-id pub-id-type="pmid">26488815</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>J</given-names></name> <name><surname>Kawamura</surname> <given-names>I</given-names></name> <name><surname>Zhu</surname> <given-names>H</given-names></name> <name><surname>Mitsuyama</surname> <given-names>M</given-names></name></person-group>. <article-title>Involvement of natural killer cells in nitric oxide production by spleen cells after stimulation with <italic>Mycobacterium bovis</italic> BCG. Study of the mechanism of the different abilities of viable and killed BCG</article-title>. <source>J Immunol</source> (<year>1995</year>) <volume>155</volume>(<issue>12</issue>):<fpage>5728</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">7499860</pub-id></citation></ref>
<ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mailliard</surname> <given-names>RB</given-names></name> <name><surname>Son</surname> <given-names>YI</given-names></name> <name><surname>Redlinger</surname> <given-names>R</given-names></name> <name><surname>Coates</surname> <given-names>PT</given-names></name> <name><surname>Giermasz</surname> <given-names>A</given-names></name> <name><surname>Morel</surname> <given-names>PA</given-names></name> <etal/></person-group> <article-title>Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function</article-title>. <source>J Immunol</source> (<year>2003</year>) <volume>171</volume>(<issue>5</issue>):<fpage>2366</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.171.5.2366</pub-id><pub-id pub-id-type="pmid">12928383</pub-id></citation></ref>
<ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastelein</surname> <given-names>RA</given-names></name> <name><surname>Hunter</surname> <given-names>CA</given-names></name> <name><surname>Cua</surname> <given-names>DJ</given-names></name></person-group>. <article-title>Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation</article-title>. <source>Annu Rev Immunol</source> (<year>2007</year>) <volume>25</volume>:<fpage>221</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104758</pub-id><pub-id pub-id-type="pmid">17291186</pub-id></citation></ref>
<ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pflanz</surname> <given-names>S</given-names></name> <name><surname>Timans</surname> <given-names>JC</given-names></name> <name><surname>Cheung</surname> <given-names>J</given-names></name> <name><surname>Rosales</surname> <given-names>R</given-names></name> <name><surname>Kanzler</surname> <given-names>H</given-names></name> <name><surname>Gilbert</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(&#x0002B;) T cells</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>16</volume>(<issue>6</issue>):<fpage>779</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(02)00324-2</pub-id></citation></ref>
<ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname> <given-names>R</given-names></name> <name><surname>van Beelen</surname> <given-names>AJ</given-names></name> <name><surname>Bakdash</surname> <given-names>G</given-names></name> <name><surname>Taanman-Kueter</surname> <given-names>EW</given-names></name> <name><surname>de Jong</surname> <given-names>EC</given-names></name> <name><surname>Kapsenberg</surname> <given-names>ML</given-names></name></person-group>. <article-title>Viral dsRNA-activated human dendritic cells produce IL-27, which selectively promotes cytotoxicity in naive CD8<sup>&#x0002B;</sup> T cells</article-title>. <source>J Leukoc Biol</source> (<year>2012</year>) <volume>92</volume>(<issue>3</issue>):<fpage>605</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0112045</pub-id><pub-id pub-id-type="pmid">22701040</pub-id></citation></ref>
<ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molle</surname> <given-names>C</given-names></name> <name><surname>Nguyen</surname> <given-names>M</given-names></name> <name><surname>Flamand</surname> <given-names>V</given-names></name> <name><surname>Renneson</surname> <given-names>J</given-names></name> <name><surname>Trottein</surname> <given-names>F</given-names></name> <name><surname>De Wit</surname> <given-names>D</given-names></name> <etal/></person-group> <article-title>IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>12</issue>):<fpage>7607</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.12.7607</pub-id><pub-id pub-id-type="pmid">17548596</pub-id></citation></ref>
<ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname> <given-names>SS</given-names></name> <name><surname>Ghaffari</surname> <given-names>AA</given-names></name> <name><surname>Cheng</surname> <given-names>G</given-names></name></person-group>. <article-title>Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>(<issue>11</issue>):<fpage>6599</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1002041</pub-id><pub-id pub-id-type="pmid">21041726</pub-id></citation></ref>
<ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pirhonen</surname> <given-names>J</given-names></name> <name><surname>Siren</surname> <given-names>J</given-names></name> <name><surname>Julkunen</surname> <given-names>I</given-names></name> <name><surname>Matikainen</surname> <given-names>S</given-names></name></person-group>. <article-title>IFN-alpha regulates toll-like receptor-mediated IL-27 gene expression in human macrophages</article-title>. <source>J Leukoc Biol</source> (<year>2007</year>) <volume>82</volume>(<issue>5</issue>):<fpage>1185</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0307157</pub-id><pub-id pub-id-type="pmid">17684041</pub-id></citation></ref>
<ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parham</surname> <given-names>C</given-names></name> <name><surname>Chirica</surname> <given-names>M</given-names></name> <name><surname>Timans</surname> <given-names>J</given-names></name> <name><surname>Vaisberg</surname> <given-names>E</given-names></name> <name><surname>Travis</surname> <given-names>M</given-names></name> <name><surname>Cheung</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>168</volume>(<issue>11</issue>):<fpage>5699</fpage>&#x02013;<lpage>708</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.168.11.5699</pub-id></citation></ref>
<ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>J</given-names></name> <name><surname>Yuan</surname> <given-names>X</given-names></name> <name><surname>Belladonna</surname> <given-names>ML</given-names></name> <name><surname>Ong</surname> <given-names>JM</given-names></name> <name><surname>Wachsmann-Hogiu</surname> <given-names>S</given-names></name> <name><surname>Farkas</surname> <given-names>DL</given-names></name> <etal/></person-group> <article-title>Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells</article-title>. <source>Cancer Res</source> (<year>2006</year>) <volume>66</volume>(<issue>17</issue>):<fpage>8887</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3448</pub-id><pub-id pub-id-type="pmid">16951206</pub-id></citation></ref>
<ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaiga</surname> <given-names>T</given-names></name> <name><surname>Sato</surname> <given-names>M</given-names></name> <name><surname>Kaneda</surname> <given-names>H</given-names></name> <name><surname>Iwakura</surname> <given-names>Y</given-names></name> <name><surname>Takayama</surname> <given-names>T</given-names></name> <name><surname>Tahara</surname> <given-names>H</given-names></name></person-group>. <article-title>Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>12</issue>):<fpage>7571</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.12.7571</pub-id><pub-id pub-id-type="pmid">17548592</pub-id></citation></ref>
<ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>P</given-names></name> <name><surname>Hu</surname> <given-names>HD</given-names></name> <name><surname>Chen</surname> <given-names>M</given-names></name> <name><surname>Peng</surname> <given-names>ML</given-names></name> <name><surname>Tang</surname> <given-names>L</given-names></name> <name><surname>Tang</surname> <given-names>KF</given-names></name> <etal/></person-group> <article-title>Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma</article-title>. <source>Mol Immunol</source> (<year>2009</year>) <volume>46</volume>(<issue>8&#x02013;9</issue>):<fpage>1654</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/j.molimm.2009.02.025</pub-id><pub-id pub-id-type="pmid">19299021</pub-id></citation></ref>
<ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname> <given-names>CH</given-names></name> <name><surname>Lee</surname> <given-names>SC</given-names></name> <name><surname>Wu</surname> <given-names>PY</given-names></name> <name><surname>Pan</surname> <given-names>WY</given-names></name> <name><surname>Su</surname> <given-names>J</given-names></name> <name><surname>Cheng</surname> <given-names>CW</given-names></name> <etal/></person-group> <article-title>Antitumor and antimetastatic activity of IL-23</article-title>. <source>J Immunol</source> (<year>2003</year>) <volume>171</volume>(<issue>2</issue>):<fpage>600</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.171.2.600</pub-id><pub-id pub-id-type="pmid">12847224</pub-id></citation></ref>
<ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname> <given-names>H</given-names></name> <name><surname>Hunter</surname> <given-names>CA</given-names></name></person-group>. <article-title>The immunobiology of interleukin-27</article-title>. <source>Annu Rev Immunol</source> (<year>2015</year>) <volume>33</volume>:<fpage>417</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112134</pub-id></citation></ref>
<ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aparicio-Siegmund</surname> <given-names>S</given-names></name> <name><surname>Garbers</surname> <given-names>C</given-names></name></person-group>. <article-title>The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity</article-title>. <source>Cytokine Growth Factor Rev</source> (<year>2015</year>) <volume>26</volume>(<issue>5</issue>):<fpage>579</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1016/j.cytogfr.2015.07.008</pub-id><pub-id pub-id-type="pmid">26195434</pub-id></citation></ref>
<ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname> <given-names>A</given-names></name> <name><surname>Hamano</surname> <given-names>S</given-names></name> <name><surname>Yamanaka</surname> <given-names>A</given-names></name> <name><surname>Hanada</surname> <given-names>T</given-names></name> <name><surname>Ishibashi</surname> <given-names>T</given-names></name> <name><surname>Mak</surname> <given-names>TW</given-names></name> <etal/></person-group> <article-title>Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment</article-title>. <source>J Immunol</source> (<year>2003</year>) <volume>170</volume>(<issue>10</issue>):<fpage>4886</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.170.10.4886</pub-id></citation></ref>
<ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname> <given-names>S</given-names></name> <name><surname>Ghilardi</surname> <given-names>N</given-names></name> <name><surname>Li</surname> <given-names>J</given-names></name> <name><surname>de Sauvage</surname> <given-names>FJ</given-names></name></person-group>. <article-title>IL-27 regulates IL-12 responsiveness of naive CD4<sup>&#x0002B;</sup> T cells through Stat1-dependent and -independent mechanisms</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2003</year>) <volume>100</volume>(<issue>25</issue>):<fpage>15047</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.2536517100</pub-id><pub-id pub-id-type="pmid">14657353</pub-id></citation></ref>
<ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hibbert</surname> <given-names>L</given-names></name> <name><surname>Pflanz</surname> <given-names>S</given-names></name> <name><surname>De Waal Malefyt</surname> <given-names>R</given-names></name> <name><surname>Kastelein</surname> <given-names>RA</given-names></name></person-group>. <article-title>IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells</article-title>. <source>J Interferon Cytokine Res</source> (<year>2003</year>) <volume>23</volume>(<issue>9</issue>):<fpage>513</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1089/10799900360708632</pub-id><pub-id pub-id-type="pmid">14565860</pub-id></citation></ref>
<ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>J</given-names></name> <name><surname>Xia</surname> <given-names>S</given-names></name> <name><surname>Sun</surname> <given-names>H</given-names></name> <name><surname>Zhang</surname> <given-names>S</given-names></name> <name><surname>Wang</surname> <given-names>J</given-names></name> <name><surname>Zhao</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>(<issue>1</issue>):<fpage>500</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1300328</pub-id><pub-id pub-id-type="pmid">23733881</pub-id></citation></ref>
<ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oniki</surname> <given-names>S</given-names></name> <name><surname>Nagai</surname> <given-names>H</given-names></name> <name><surname>Horikawa</surname> <given-names>T</given-names></name> <name><surname>Furukawa</surname> <given-names>J</given-names></name> <name><surname>Belladonna</surname> <given-names>ML</given-names></name> <name><surname>Yoshimoto</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma</article-title>. <source>Cancer Res</source> (<year>2006</year>) <volume>66</volume>(<issue>12</issue>):<fpage>6395</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4087</pub-id><pub-id pub-id-type="pmid">16778218</pub-id></citation></ref>
<ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiyo</surname> <given-names>M</given-names></name> <name><surname>Shimozato</surname> <given-names>O</given-names></name> <name><surname>Yu</surname> <given-names>L</given-names></name> <name><surname>Kawamura</surname> <given-names>K</given-names></name> <name><surname>Iizasa</surname> <given-names>T</given-names></name> <name><surname>Fujisawa</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals</article-title>. <source>Int J Cancer</source> (<year>2005</year>) <volume>115</volume>(<issue>3</issue>):<fpage>437</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.20848</pub-id><pub-id pub-id-type="pmid">15688376</pub-id></citation></ref>
<ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cocco</surname> <given-names>C</given-names></name> <name><surname>Pistoia</surname> <given-names>V</given-names></name> <name><surname>Airoldi</surname> <given-names>I</given-names></name></person-group>. <article-title>Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia</article-title>. <source>Crit Rev Oncol Hematol</source> (<year>2012</year>) <volume>83</volume>(<issue>3</issue>):<fpage>310</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.critrevonc.2011.11.006</pub-id><pub-id pub-id-type="pmid">22177566</pub-id></citation></ref>
<ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>L</given-names></name> <name><surname>Wang</surname> <given-names>S</given-names></name> <name><surname>Shan</surname> <given-names>B</given-names></name> <name><surname>Shao</surname> <given-names>L</given-names></name> <name><surname>Sato</surname> <given-names>A</given-names></name> <name><surname>Kawamura</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells</article-title>. <source>Scand J Immunol</source> (<year>2008</year>) <volume>68</volume>(<issue>1</issue>):<fpage>22</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-3083.2008.02111.x</pub-id><pub-id pub-id-type="pmid">18482209</pub-id></citation></ref>
<ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Z</given-names></name> <name><surname>Liu</surname> <given-names>JQ</given-names></name> <name><surname>Talebian</surname> <given-names>F</given-names></name> <name><surname>Wu</surname> <given-names>LC</given-names></name> <name><surname>Li</surname> <given-names>S</given-names></name> <name><surname>Bai</surname> <given-names>XF</given-names></name></person-group>. <article-title>IL-27 enhances the survival of tumor antigen-specific CD8<sup>&#x0002B;</sup> T cells and programs them into IL-10-producing, memory precursor-like effector cells</article-title>. <source>Eur J Immunol</source> (<year>2013</year>) <volume>43</volume>(<issue>2</issue>):<fpage>468</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201242930</pub-id><pub-id pub-id-type="pmid">23225163</pub-id></citation></ref>
<ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsui</surname> <given-names>M</given-names></name> <name><surname>Kishida</surname> <given-names>T</given-names></name> <name><surname>Nakano</surname> <given-names>H</given-names></name> <name><surname>Yoshimoto</surname> <given-names>K</given-names></name> <name><surname>Shin-Ya</surname> <given-names>M</given-names></name> <name><surname>Shimada</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>6</issue>):<fpage>2523</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2793</pub-id><pub-id pub-id-type="pmid">19244121</pub-id></citation></ref>
<ref id="B77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salcedo</surname> <given-names>R</given-names></name> <name><surname>Stauffer</surname> <given-names>JK</given-names></name> <name><surname>Lincoln</surname> <given-names>E</given-names></name> <name><surname>Back</surname> <given-names>TC</given-names></name> <name><surname>Hixon</surname> <given-names>JA</given-names></name> <name><surname>Hahn</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8<sup>&#x0002B;</sup> T cells</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>173</volume>(<issue>12</issue>):<fpage>7170</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.173.12.7170</pub-id><pub-id pub-id-type="pmid">15585838</pub-id></citation></ref>
<ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laroni</surname> <given-names>A</given-names></name> <name><surname>Gandhi</surname> <given-names>R</given-names></name> <name><surname>Beynon</surname> <given-names>V</given-names></name> <name><surname>Weiner</surname> <given-names>HL</given-names></name></person-group>. <article-title>IL-27 imparts immunoregulatory function to human NK cell subsets</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>(<issue>10</issue>):<fpage>e26173</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0026173</pub-id><pub-id pub-id-type="pmid">22039443</pub-id></citation></ref>
<ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziblat</surname> <given-names>A</given-names></name> <name><surname>Domaica</surname> <given-names>CI</given-names></name> <name><surname>Spallanzani</surname> <given-names>RG</given-names></name> <name><surname>Iraolagoitia</surname> <given-names>XL</given-names></name> <name><surname>Rossi</surname> <given-names>LE</given-names></name> <name><surname>Avila</surname> <given-names>DE</given-names></name> <etal/></person-group> <article-title>IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness</article-title>. <source>Eur J Immunol</source> (<year>2015</year>) <volume>45</volume>(<issue>1</issue>):<fpage>192</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201444699</pub-id><pub-id pub-id-type="pmid">25308526</pub-id></citation></ref>
<ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>ME</given-names></name> <name><surname>Caligiuri</surname> <given-names>MA</given-names></name></person-group>. <article-title>Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response</article-title>. <source>Blood</source> (<year>1997</year>) <volume>89</volume>(<issue>3</issue>):<fpage>910</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9028322</pub-id></citation></ref>
<ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fehniger</surname> <given-names>TA</given-names></name> <name><surname>Shah</surname> <given-names>MH</given-names></name> <name><surname>Turner</surname> <given-names>MJ</given-names></name> <name><surname>VanDeusen</surname> <given-names>JB</given-names></name> <name><surname>Whitman</surname> <given-names>SP</given-names></name> <name><surname>Cooper</surname> <given-names>MA</given-names></name> <etal/></person-group> <article-title>Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>162</volume>(<issue>8</issue>):<fpage>4511</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">10201989</pub-id></citation></ref>
<ref id="B82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fehniger</surname> <given-names>TA</given-names></name> <name><surname>Cooper</surname> <given-names>MA</given-names></name> <name><surname>Nuovo</surname> <given-names>GJ</given-names></name> <name><surname>Cella</surname> <given-names>M</given-names></name> <name><surname>Facchetti</surname> <given-names>F</given-names></name> <name><surname>Colonna</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>CD56<sup>bright</sup> natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity</article-title>. <source>Blood</source> (<year>2003</year>) <volume>101</volume>(<issue>8</issue>):<fpage>3052</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2002-09-2876</pub-id><pub-id pub-id-type="pmid">12480696</pub-id></citation></ref>
<ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname> <given-names>WE</given-names></name> <name><surname>Dierksheide</surname> <given-names>JE</given-names></name> <name><surname>Jabbour</surname> <given-names>S</given-names></name> <name><surname>Anghelina</surname> <given-names>M</given-names></name> <name><surname>Bouchard</surname> <given-names>P</given-names></name> <name><surname>Ku</surname> <given-names>G</given-names></name> <etal/></person-group> <article-title>Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction</article-title>. <source>Blood</source> (<year>2000</year>) <volume>96</volume>(<issue>4</issue>):<fpage>1465</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">10942393</pub-id></citation></ref>
<ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname> <given-names>MJ</given-names></name> <name><surname>Swann</surname> <given-names>J</given-names></name> <name><surname>Kelly</surname> <given-names>JM</given-names></name> <name><surname>Cretney</surname> <given-names>E</given-names></name> <name><surname>Yokoyama</surname> <given-names>WM</given-names></name> <name><surname>Diefenbach</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>200</volume>(<issue>10</issue>):<fpage>1325</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20041522</pub-id><pub-id pub-id-type="pmid">15545356</pub-id></citation></ref>
<ref id="B85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lauwerys</surname> <given-names>BR</given-names></name> <name><surname>Renauld</surname> <given-names>JC</given-names></name> <name><surname>Houssiau</surname> <given-names>FA</given-names></name></person-group>. <article-title>Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18</article-title>. <source>Cytokine</source> (<year>1999</year>) <volume>11</volume>(<issue>11</issue>):<fpage>822</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1006/cyto.1999.0501</pub-id><pub-id pub-id-type="pmid">10547269</pub-id></citation></ref>
<ref id="B86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabbi</surname> <given-names>M</given-names></name> <name><surname>Carbotti</surname> <given-names>G</given-names></name> <name><surname>Ferrini</surname> <given-names>S</given-names></name></person-group>. <article-title>Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP</article-title>. <source>J Leukoc Biol</source> (<year>2015</year>) <volume>97</volume>(<issue>4</issue>):<fpage>665</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.5RU0714-360RR</pub-id><pub-id pub-id-type="pmid">25548255</pub-id></citation></ref>
<ref id="B87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalinski</surname> <given-names>P</given-names></name> <name><surname>Giermasz</surname> <given-names>A</given-names></name> <name><surname>Nakamura</surname> <given-names>Y</given-names></name> <name><surname>Basse</surname> <given-names>P</given-names></name> <name><surname>Storkus</surname> <given-names>WJ</given-names></name> <name><surname>Kirkwood</surname> <given-names>JM</given-names></name> <etal/></person-group> <article-title>Helper role of NK cells during the induction of anticancer responses by dendritic cells</article-title>. <source>Mol Immunol</source> (<year>2005</year>) <volume>42</volume>(<issue>4</issue>):<fpage>535</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.molimm.2004.07.038</pub-id><pub-id pub-id-type="pmid">15607810</pub-id></citation></ref>
<ref id="B88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>JL</given-names></name> <name><surname>Berk</surname> <given-names>E</given-names></name> <name><surname>Edwards</surname> <given-names>RP</given-names></name> <name><surname>Kalinski</surname> <given-names>P</given-names></name></person-group>. <article-title>IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8<sup>&#x0002B;</sup> T cells to the tumor microenvironment</article-title>. <source>Cancer Res</source> (<year>2013</year>) <volume>73</volume>(<issue>15</issue>):<fpage>4653</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-4366</pub-id><pub-id pub-id-type="pmid">23761327</pub-id></citation></ref>
<ref id="B89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname> <given-names>K</given-names></name> <name><surname>Tsutsui</surname> <given-names>H</given-names></name> <name><surname>Yoshimoto</surname> <given-names>T</given-names></name> <name><surname>Adachi</surname> <given-names>O</given-names></name> <name><surname>Yoshida</surname> <given-names>N</given-names></name> <name><surname>Kishimoto</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Defective NK cell activity and Th1 response in IL-18-deficient mice</article-title>. <source>Immunity</source> (<year>1998</year>) <volume>8</volume>(<issue>3</issue>):<fpage>383</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(00)80543-9</pub-id><pub-id pub-id-type="pmid">9529155</pub-id></citation></ref>
<ref id="B90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaix</surname> <given-names>J</given-names></name> <name><surname>Tessmer</surname> <given-names>MS</given-names></name> <name><surname>Hoebe</surname> <given-names>K</given-names></name> <name><surname>Fuseri</surname> <given-names>N</given-names></name> <name><surname>Ryffel</surname> <given-names>B</given-names></name> <name><surname>Dalod</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Priming of NK cells by IL-18</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>(<issue>3</issue>):<fpage>1627</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.3.1627</pub-id></citation></ref>
<ref id="B91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semino</surname> <given-names>C</given-names></name> <name><surname>Angelini</surname> <given-names>G</given-names></name> <name><surname>Poggi</surname> <given-names>A</given-names></name> <name><surname>Rubartelli</surname> <given-names>A</given-names></name></person-group>. <article-title>NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>2</issue>):<fpage>609</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2004-10-3906</pub-id><pub-id pub-id-type="pmid">15802534</pub-id></citation></ref>
<ref id="B92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname> <given-names>SJ</given-names></name> <name><surname>Sullivan</surname> <given-names>BM</given-names></name> <name><surname>Stemmann</surname> <given-names>C</given-names></name> <name><surname>Satoskar</surname> <given-names>AR</given-names></name> <name><surname>Sleckman</surname> <given-names>BP</given-names></name> <name><surname>Glimcher</surname> <given-names>LH</given-names></name></person-group>. <article-title>Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells</article-title>. <source>Science</source> (<year>2002</year>) <volume>295</volume>(<issue>5553</issue>):<fpage>338</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1126/science.1065543</pub-id><pub-id pub-id-type="pmid">11786644</pub-id></citation></ref>
<ref id="B93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>J</given-names></name> <name><surname>Wei</surname> <given-names>M</given-names></name> <name><surname>Boyd</surname> <given-names>Z</given-names></name> <name><surname>Lehmann</surname> <given-names>EB</given-names></name> <name><surname>Trotta</surname> <given-names>R</given-names></name> <name><surname>Mao</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Transcriptional control of human T-BET expression: the role of Sp1</article-title>. <source>Eur J Immunol</source> (<year>2007</year>) <volume>37</volume>(<issue>9</issue>):<fpage>2549</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200737088</pub-id><pub-id pub-id-type="pmid">17705132</pub-id></citation></ref>
<ref id="B94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname> <given-names>JL</given-names></name> <name><surname>George</surname> <given-names>TC</given-names></name> <name><surname>Hagman</surname> <given-names>J</given-names></name> <name><surname>Gapin</surname> <given-names>L</given-names></name></person-group>. <article-title>Temporal dissection of T-bet functions</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>6</issue>):<fpage>3457</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.6.3457</pub-id><pub-id pub-id-type="pmid">17339440</pub-id></citation></ref>
<ref id="B95"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>R</given-names></name> <name><surname>Jaw</surname> <given-names>JJ</given-names></name> <name><surname>Stutzman</surname> <given-names>NC</given-names></name> <name><surname>Zou</surname> <given-names>Z</given-names></name> <name><surname>Sun</surname> <given-names>PD</given-names></name></person-group>. <article-title>Natural killer cell-produced IFN-gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1</article-title>. <source>J Leukoc Biol</source> (<year>2012</year>) <volume>91</volume>(<issue>2</issue>):<fpage>299</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0611308</pub-id></citation></ref>
<ref id="B96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname> <given-names>AC</given-names></name> <name><surname>High</surname> <given-names>FA</given-names></name> <name><surname>Hutchins</surname> <given-names>AS</given-names></name> <name><surname>Lee</surname> <given-names>HW</given-names></name> <name><surname>Villarino</surname> <given-names>AV</given-names></name> <name><surname>Livingston</surname> <given-names>DM</given-names></name> <etal/></person-group> <article-title>Role of T-bet in commitment of TH1 cells before IL-12-dependent selection</article-title>. <source>Science</source> (<year>2001</year>) <volume>292</volume>(<issue>5523</issue>):<fpage>1907</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1126/science.1059835</pub-id><pub-id pub-id-type="pmid">11397944</pub-id></citation></ref>
<ref id="B97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afkarian</surname> <given-names>M</given-names></name> <name><surname>Sedy</surname> <given-names>JR</given-names></name> <name><surname>Yang</surname> <given-names>J</given-names></name> <name><surname>Jacobson</surname> <given-names>NG</given-names></name> <name><surname>Cereb</surname> <given-names>N</given-names></name> <name><surname>Yang</surname> <given-names>SY</given-names></name> <etal/></person-group> <article-title>T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4<sup>&#x0002B;</sup> T cells</article-title>. <source>Nat Immunol</source> (<year>2002</year>) <volume>3</volume>(<issue>6</issue>):<fpage>549</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1038/ni794</pub-id></citation></ref>
</ref-list>
</back>
</article>